Abstract:Considerable knowledge has recently accumulated on the mechanism by which Helicobacter pylori (H. pylori) induces chronic gastritis. Although H. pylori is not an invasive bacterium, soluble surface constituents can provoke pepsinogen release from gastric chief cells or trigger local inflammation in the underlying tissue. Urease appears to be one of the prime chemoattractants for recruitment and activation of inflammatory cells. Release of cytokines, such as tumor necrosis factor alpha, interleukin 1 and 6, and oxygen radicals, leads to a further tissue inflammation accompanied by a potent systemic IgA and IgG type of immune response. Chronic inflammation and antigens on glandular epithelial cells lead to a progressive destruction with loss of the epithelial barrier function. Within the gastric mucosa, patches of intestinal metaplasia develop, which may be a risk factor for subsequent development of gastric carcinoma. Hyperacidity in duodenal ulcer patients induces gastric metaplasia in the duodenal bulb, which represents a target for H. pylori colonization and ulcer formation. H. pylori can be detected in the majority of patients with peptic ulcers and, compared to age-matched healthy people, it is also found more often in patients with dyspepsia and gastric carcinoma. Although H. pylori can be detected in healthy people, the marked reduction of the ulcer recurrence rate by eradication of H. pylori (80 percent versus 20 percent relapse within one year) suggests that H. pylori is a major risk factor for duodenal ulcer formation. The potential role of H. pylori in non-ulcer dyspepsia and carcinogenesis is under investigation. Current regimens aimed at eradicating H. pylori use a combination of several drugs that are potentially toxic. Since the risk of complications may exceed the potential benefit in most patients, eradication treatment should be limited to clinical trials and to patients with aggressive ulcer disease. New drug regimens, e.g., the combination of proton pump inhibitors with one antibiotic, may provide less toxic alternatives. Beyond ulcer treatment, effective and well-tolerated eradication regimens may have a place in prophylaxis of gastric carcinoma.

An overview of mechanism research on Helicobacter pylori pathogenic factors

Research Progress on Pathogenic Mechanism of Helicobacter Pylori

Molecular Mechanism of Helicobacter pylori Infection

p27(kip1) upregulated by hnRNPC1/2 antagonizes CagA (a virulence factor of Helicobacter pylori)-mediated pathogenesis.

Virulence factors and pathogenic mechanism of Helicobacter pylori

Helicobacter pylori: an up-to-date overview on the virulence and pathogenesis mechanisms

Review: Pathogenesis of Helicobacter pylori infection

Pathogenic Factors Related to Helicobacter Pylori Colonization

Immunological Mechanism of Helicobacter Pylori Infection Induced Gastrointestinal Diseases

Adhesion and Invasion of Gastric Mucosa Epithelial Cells by Helicobacter Pylori

Helicobacter pylori virulence factors: facts and fantasies.

Recent progress on the association of Helicobacter pylori virulence factors and human genetic susceptibility with risk of gastric cancer and precancerous lesions

Inflammation of Antral Mucosa and Inflammatory Mediators of Duodenal Ulcer with Helicobacter Pylori Infection

Impact of Helicobacter pylori Virulence Factors on the Host Immune Response and Gastric Pathology

Mechanisms of disease: Helicobacter pylori virulence factors

Infiltration to infection: key virulence players of Helicobacter pylori pathogenicity

Helicobacter pylori Virulence Factors Exploiting Gastric Colonization and its Pathogenicity

Pathophysiology and clinical relevance of Helicobacter pylori

Pathogenomics of Helicobacter pylori

Outer Membrane Vesicles Secreted by Helicobacter pylori Transmitting Gastric Pathogenic Virulence Factors

Helicobacter pylori Virulence Factors—Mechanisms of Bacterial Pathogenicity in the Gastric Microenvironment